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Non-subcutaneous ordinary lipomas, including subfascial and
intramuscular lipomas, account for 40% of ordinary lipomas
(Fletcher et al, 1996). These tumours, also called deep-seated ordi-
nary lipomas, may achieve a large size, particularly the intramus-
cular ones. In these cases the differential diagnosis between large
deep-seated ordinary lipoma (LDSL) and the lipoma-like subtype
of well differentiated liposarcoma (LL-WDL) may be difficult due
to their similar histologic characteristics and focality of nuclear
atypia (Rosai et al, 1996).
Furthermore, although lipomatous tumours in the retroperi-
toneum are mainly represented by well differentiated liposarcomas
(WDL), lipomas may also appear at this site (DeWeerd et al,
1952). Thus, it would be valuable to support histologic classifica-
tion with a simple immunophenotypic procedure in arguable cases.
The 12q13–15 chromosome region is complex and contains
several genes that are amplified or rearranged in lipomatous
tumours such as the MDM2, CDK4, SAS or CHOP and HMGI-C
(High Mobility Group I-C protein) genes respectively (Smith et al,
1992; Forus et al, 1993; Khatib et al, 1993; Leach et al, 1993;
Schoenmakers et al, 1995). HMGI-C gene translocations have
been suggested to facilitate the development of lipomas
(Schoenmakers et al, 1995; Tkachenko et al, 1997). On the other
hand, MDM2 and CDK4 amplification and overexpression, which
in turn correlate with the presence of chromosomes containing
material from 12q, have been indicated as frequent in WDL (Dal
Cin et al, 1993; Khatib et al, 1993; Pedeutour et al, 1993; Hunter
and Pines, 1994; Nilbert et al, 1994; Pilotti et al, 1997, 1998).
More recently it has also been shown that overexpression of 12q
sequences is a recurrent finding in WDL but not in lipoma
(Mandahl et al, 1996; Szymanska et al, 1997).
Here we applied a MDM2/CDK4 gene-product-based
immunophenotypic analysis, complemented in suitable cases by
molecular and cytogenetic approaches, to a series of LL-WDLs
and of LDSLs for comparison purposes.
The results show that MDM2/CDK4 immunophenotyping may
assist in the differential diagnosis of the two entities.
MATERIALS AND METHODS
Materials
The case material consisted of 21 cases of LL-WDL including 12
primary and nine recurrent tumours and 19 primary LDSL from
patients treated at our institution between 1988 and 1997. Eleven
cases had been included in a previously reported series (cases 5,
9–13, 17–21) (Pilotti et al, 1997). All cases have been reviewed in
order to verify the diagnosis and select representative tumoural
samples for immunophenotypic analysis. The morphologic diag-
noses were confirmed in all cases following the criteria of the
pathologists of the CHAMP study group (Willen et al, 1998) and
the criteria of Evans (1988) updated by Mentzel and Fletcher
(1995). The cases were consecutive according to the criteria of
selection: histologic subtype (LL-WDL) for liposarcoma and size
(> 7 cm in largest diameter) for lipoma.
The age and sex of the patients as well as the location, type of
specimens analysed (primary, recurrence) and size of the tumours
are presented in Tables 2 (LL-WDL) and 3 (LDSL).
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DOI: 10.1054/ bjoc.1999.1090, available online at http://www.idealibrary.com on Histologically, the lipoma-like component constituted 100% of
the tumour in 16 out of 21 LL-WDLS including primaries and
recurrences. In three retroperitoneal cases a sclerosing subtype
component constituted from 20% (case no. 3) to 30% (cases 4 and
5) of the total of sampled tumours respectively, and in two non-
retroperitoneal tumours (cases 1 and 7) this component corre-
sponded to less than 20%. In two cases radiotherapy (case no. 6)
and chemotherapy (case no. 11) were performed before surgical
resection of tumour samples for study.
Immunocytochemistry, karyotyping and Southern blot
analysis
Immunocytochemistry, karyotyping and Southern blot analysis
were carried out as previously described (Pilotti et al, 1997, 1998).
For immunostaining analysis from 2–8 LL-WDLs samples (for
details see Table 2) and all samples of LDSLs were processed.
Suitable material for molecular analysis was available in nine
out of 21 (42.8%) LL-WDLs and in seven out of 19 (36.8%)
LDSLs. The material suitable for classic cytogenetic analysis
accounted for three out of 21 and two out of 19 cases in the two
groups respectively.
For Southern blotting, DNA was digested with the restriction
enzyme  KpnI. Radiolabelled probes were: a 258-nucleotide
MDM2 genomic fragment amplified by PCR with primers within
exons 2 and 3 of the gene (Zauberman et al, 1995), a 534-
nucleotide CDK4 genomic fragment generated by polymerase
chain reaction (PCR) using the primers described by Khatib 
et al. (1993), and a PCR-generated TP53 genomic fragment
spanning nucleotides 13040–13450 of the gene. Hybridization
with each probe resulted in a single band, which was of about 
23 kb for the MDM2 gene, 1.5 kb for the CDK4 gene, and about
12 kb for TP53.
Fluorescence in situ hybridization
Interphase fluorescence in situ hybridization (FISH) analysis was
carried out on cryopreserved cytologic scrapings of the surgical
specimen. Each slide was hybridized with the biotinylated probe
Amplification unit probe 12q13 (Li Biomedical Corporation)
corresponding to the amplicon MDM2,  SAS and  GLI genes.
Hybridization was performed according to Lichter et al (1990),
Mezzelani et al (1996) and the manufacturer’s recommendations.
The sample was scored as amplified when the single nuclei
showed more than two signals. Metaphase FISH analysis was
performed using whole chromosome 12 and 6 paintings
(CAMBIO, Cambridge, UK) using standard procedures (Pilotti
et al, 1997, 1998). Overall, cytogenetic analysis and/or interphase
and metaphase FISH were performed in eight out of 21 cases of
LL-WDL and in six out of 19 cases of LDSL.
RESULTS
Table 1 summarizes the main clinical data, treatment and outcome
on LL-WDLs. Thirteen out of 21 (61.9%) patients experienced
from one to three recurrences, whereas only one case of recurrence
was observed among the LDSLs (case no. 33). Given the
uneventful follow-up of the remaining 18 cases a dedicated table
has not been produced.
Immunophenotyping (Table 2) shows MDM2/CDK4 expression
in 18 of the 21 cases (85.7%) and CDK4 immunoreactivity in
100% of the cases. The analysis of two samples was sufficient to
achieve information about the immunophenotypic profile in the
majority of the cases. In the three MDM2-CDK4+ cases (Table 2,
cases 9, 14 and 16) all available samples were immunostained in
order to confirm the null MDM2 immunophenotype.
All LDSL samples analysed turned out to be MDM2-
CDK4- (Table 3). Tables 2 and 3 and Figure 1A–F summarize
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Table 1 Lipoma-like well differentiated liposarcomas: clinical features
Case no. Age/Gender Site Primary treatment Number/Time of local Treatment of recurrence Follow-up
recurrence
1 64/F Thorax wall Resection 2, at 7 and 9 years Resection + CT NED, 1 year
2 84/M Thigh Resection – – NED, 1 year
3 42/M Retroperitoneum Resection – – Lost
4 36/F Retroperitoneum Resectionb 1, at 1 year Resection + RT AWD, 2 years
5 49/M Retroperitoneum Resectionb 3, at 4, 6 and 9 years Resection AWD, 9 years
6 50/M Retroperitoneum RTa resectionb,c 1, at 1 year RT + resection NED, 2 years
7 59/M Thigh Resectionb 1, at 4 years Resection + CT NED, 1.5 years
8 67/M Retroperitoneum Resectionb 1, at 3 years Resection NED, 5 years
9 56/F Retroperitoneum Resection – – NED, 4 years
10 57/F Retroperitoneum Resectionb 1, at 3 years Resection lost
11 64/M Retroperitoneum CTa resectionb 2, at 2 and 5 years Resection + RT AWD, 5 years
12 46/F Retroperitoneum Resectionb 2, at 3 and 6 years Resection + CT + RT AWD, 9 years
13 51/F Retroperitoneum Resectionb 1, at 3 years Resection NED, 6 years
14 62/M Thigh Resection – – NED, 2 years
15 72/M Thigh Resection 2, at 4 and 7 years Resection NED, 9 years
16 52/M Shoulder Resection – – lost
17 66/M Thigh Resection 3, at 5, 12 and 13 years Resection + CT AWD, 2, 5 years
18 45/F Arm Resection – – NED, 1, 5 years
19 28/M Thigh Resection – – NED, 9 years
20 26/F Buttock Resection – – NED, 9 years
21 44/F Pelvis Resection 1, at 1 years CT lost
RT = radiotherapy; CT = chemotherapy; NED = no evidence of disease; AWD = alive with disease. aFor details see text. bPrimary tumour resection performed
elsewhere. cSynchronous renal carcinoma.immunophenotypic, genotypic and cytogenetic results. In keeping
with immunophenotypic findings amplification of both MDM2
and  CDK4 genes was observed in the nine LL-WDLs and no
abnormality of the two genes was observed in the seven LDSLs
analysed by Southern blot. Interestingly, case no. 9, categorized
routinely on morphologic grounds as lipoma and reported as
MDM2-negative in a previous investigation (Pilotti et al, 1997),
showed CDK4 immunoreactivity (Figure 1C) and CDK4 as well
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Table 2 Lipoma-like well differentiated liposarcomas: immunophenotyping, molecular and cytogenetic features (21 cases
Immunocytochemistry Southern blot analysis
Specimens analysed:
Case no. primary (P), MDM2 CDK4 MDM2 CDK4 Interphase Cytogenetics
recurrences (R) a FISH
1 P (2/7) + + + + A
2 P (2/6) + + + + 48,XY,+r(12)´2/2n+,+der(12),+r(12),+d min
3 P (2/9) + + + + A
4 R (2/17) + + + + A
5 R (2/13) + + + +
6 R (2/26) + + + + A
7 P (2/11) + + + + A 48,XY,+r(12)´2/2n+,+der(12),+r(12),+d min
8 R (2/23) + + + +
9 P (7/7) – + + +
10 R (2/7) + +
11 R (2/6) + +
12 R (2/5) + +
13 R (2/6) + +
14 P (7/7) – + 48,XY,+2r
15 P (2/26) + +
16 P (8/8) – +
17 P (2/8) + +
18 P (2/4) + +
19 P (2/4) + +
20 P (2/9) + +
21 R (2/5) + +
aIn brackets: number of samples immunostained for MDM2 and CDK4 by the total of specimens sampled for each tumour. A: features consistent with gene
amplification.
Table 3 Lipomas: immunophenotyping, molecular and cytogenetic features (19 cases)
Immunocytochemistry Southern blot analysis
Interphase Cytogenetics
Case no. Age gender Site size (cm) MDM2 CDK4 MDM2 CDK4 FISH
22 54/F Thigh 18 – – – –
23 79/M Neck 7 – – – –
24 56/M Lower back 10 – – – – TS
25 40/M Thigh 11 – – – – TS
26 69/M Arm 7 – – – – NE 46,XY,add (12)(q13)
27 67/M Thorax region 10 – – – –
28 66/M Abdominal wall 30 – – – –
29 39/M Thorax region 17 – –
30 52/M Thigh 7 – –
31 57/F Abdominal wall 13 – –
32 66/M Lower back 13 – –
33 76/M Abdominal wall 10 – –
34 31/M Thorax wall 7 – –
35 64/F Shoulder 9 – –
36 59/M Lower back 11 – –
37 68/M Shoulder 12 – –
38 56/F Thorax region 7 – –
39 53/F Shoulder 10 – –
40 59/M Thigh 21 – – TS 46,XY t(6;18)(q13–14;q21)
NE = not evaluable; TS = two signals.as  MDM2 gene amplification (Figure 1F) despite MDM2 null
immunophenotype. In light of these findings the case, which
since the time of the first categorization showed no com-
pletely convincing benign features, was reconsidered as possible
LL-WDL and included in Table 1.
FISH was successfully applied in the five cases of LL-WDL and
in three out of four cases of LDSL. Nuclei obtained from the
LL-WDL cases showed an amplification level ranging from eight
to 15 signals (Figure 1B). Although FISH cannot demonstrate that
the amplified gene is MDM2 (since the probe covered MDM2, SAS
and GLI sequences), this assumption is supported by the immuno-
staining (Figure 1A) and Southern blot results obtained with the
MDM2-specific probe (Figure 1E). By contrast, nuclei from LDSL
showed two normal signals corresponding to the two copies of the
region (1D). Karyotypic analysis showed the presence of ring
chromosomes in three LL-WDL cases analysed; two of them (case
no. 2 and no. 14) also showed the presence of a minor clone (10%
of the total metaphases), that contained ring chromosomes, giant
markers and double minutes. In these two cases FISH experiments
with a whole chromosome 12 probe completely painted the ring
chromosomes of the major clone, and the ring chromosomes, the
double minutes and part of the giant markers of the minor clone. A
translocation with a breakpoint at band q13 of chromosome 12
was found in case no. 26 of LDSL, and a novel translocation
t(6;18)(q13–14; q21) was found in case no. 40 of LDSL.
DISCUSSION
On cytogenetic grounds, about two-thirds of ordinary lipomas and
most WDLs share aberrations in the chromosome 12q13–15
segment (Mandahl et al, 1996). However, in lipomas the majority
of these aberrations are consistent with the creation of chimaeric
genes made up of a fusion of the HMG1-C gene in 12q15 with
multiple partners, although the LPP (lipoma preferred partner)
gene, at 3q27–28, is preferentially involved (Petit et al, 1996). On
the other hand, in WDLs the aberrations of chromosome 12q are
represented by the amplification of genes spanning the 13q–15q
region (Berner et al, 1997; Dei Tos and Dal Cin, 1997). Assum-
ing that these findings represent two different transformation
pathways, and taking into account that MDM2 and CDK4 gene
amplification parallels the presence of ring chromosomes as well
as MDM2 and CDK4 protein overexpression (Pilotti et al, 1997,
1998), it is reasonable to assume that immunophenotyping will
assist in the differential diagnosis between LL-WDL and LDSL.
The present data confirm this assumption that, in turn, makes
immunophenotype more consistent with biology than morphology.
Similar results have recently been observed using different, less
easily handled and not always applicable methodologic
approaches, such as classical cytogenetic methods and compara-
tive genomic hybridization (CGH) (Suijkerbuijk et al, 1994;
Mandahl et al, 1996; Szymanska et al, 1997).
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Figure 1 (A) and inset: mdm2 expression, and (B) gene amplification by FISH, in one of the LL-WDL cases (case no. 8). (C) cdk4 immunoreactivity, in case
no. 9 (previously classified as LDSL) null for mdm2 but showing coamplification at MDM2 and CDK4 genes by Southern blot (see below). (D) FISH showing two
normal signals in one of the LDSL cases (case no. 24). (E) Southern blot analysis of MDM2 and CDK4 amplification in eight cases of LL-WDL. Hybridization
with MDM2 or CDK4 probe reveals amplification of both genes in the tumour DNA of all cases. (F) Southern blot hybridization of 1 LL-WDL (previously classified
as LDSL, case no. 9) and seven cases of LDSL. None of the LDSLs show amplification of MDM2 and CDK4 while the two genes are coamplified in the LL-WDL.
As a control for the loading amount of DNA the blots in E and F were hybridized with a TP53 probe. C+: SJSA-1 osteosarcoma cell line positive for MDM2 and
CDK4 amplification. C–: normal peripheral blood cells. The numbers on the bottom of the blots are in accordance with Tables 2 and 3Support to our immunophenotypic results is provided by the
molecular and cytogenetic data which fitted with the immuno-
phenotypic information in all the examined cases. For the MDM2
gene, the Southern blot data were further confirmed by FISH which
showed amplification in the 5 LL-WDL analysed. By contrast,
FISH revealed only two signals in the three LDSLs successfully
analysed. Moreover, in one of these three cases of lipoma (case no.
26) the diagnosis was further supported by the presence of a
translocation with a breakpoint at q13 of chromosome 12, a cytoge-
netic feature characteristic of lipoma (Heim and Mitelman, 1995),
and a novel translocation t(6;18)(q13–14;q21) was found in a
second case. Even though rearrangement of 12q13–14 and 6p are
the most frequently found in lipoma, other observations which do
not involve these chromosome arms have been reported (Willen et
al, 1998). The finding that the MDM2 antibody failed to decorate
tumour cells in two cases of LL-WDL (cases 14 and 16 respec-
tively), points out the value of CDK4 gene assessment in differen-
tial diagnosis, and reconfirms that even amplification excluding
MDM2 may contribute to transformation (Pilotti et al, 1998). It is
rather unlikely, in fact, that immunostaining failure be ascribed to
cellular variation as immunostaining was performed in all samples.
However, this possibility cannot be completely excluded in case no.
9 because of the discrepancy between immunochemical and molec-
ular analyses regarding the MDM2 amplification which, on the
other hand, could suggest that an MDM2 gene amplification can
occur without the expression of the relative product.
In conclusion our results support the notion that MDM2 and
CDK4 immunophenotyping may represent a valuable ancillary
procedure in the assessment of arguable LDSL cases. This diag-
nostic approach will also clarify if retroperitoneal lipoma represents
an anecdotal occurrence or a reality (DeWeerd and Dockerty, 1952).
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